Inclusion Criteria:
  -  Colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease.
  -  Females of childbearing potential: negative urine pregnancy test
  -  Ability to provide informed consent
  -  Ability to collaborate with planned follow-up (transportation, compliance history, etc.)
  -  Use of contraception through the study exit visit (week 28)
Exclusion Criteria:
  -  History of anal, vulvar, cervical or oropharyngeal HPV cancers
  -  History of any other malignancy, except for non-melanoma skin lesions
  -  Cluster of differentiation 4 (CD4) count < 200 at the time of screening for eligibility.
  -  Unable to provide informed consent
  -  Currently receiving systemic chemotherapy or radiation therapy for another cancer.
  -  Pregnant females